Using a nonparametric multilevel latent Markov model to evaluate diagnostics for trachoma by Koukounari, Artemis et al.
  
Artemis Koukounari,  Irini Moustaki, Nicholas C. Grassly, 
Isobel M. Blake, María-Gloria Basáñez, Manoj Gambhir, 
David C.W. Mabey, Robin L. Bailey, Matthew J. Burton, 
Anthony W. Solomon, and Christl A. Donnelly 
Using a nonparametric multilevel latent 
Markov model to evaluate diagnostics for 
trachoma 
 
Article (Published version) 
(Refereed) 
 
 
 
 
Original citation: 
Koukounari, Artemis, Moustaki, Irini, Grassly, Nicholas C., Blake, Isobel M., Basanez, Maria-
Gloria, Gambhir, Manoj, Mabey, David, Bailey, Robin L., Burton, Matthew J., Solomon, Anthony 
W. and Donnelly, Christl A. (2013) Using a nonparametric multilevel latent Markov model to 
evaluate diagnostics for trachoma. American Journal of Epidemiology, 177 (9). pp. 913-922. 
ISSN 0002-9262 DOI: 10.1093/aje/kws345 
 
© 2013 The Authors. Published by Oxford University Press on behalf of the Johns Hopkins 
Bloomberg School of Public Health. 
 
This version available at: http://eprints.lse.ac.uk/50429/ 
Available in LSE Research Online: April 2014 
 
LSE has developed LSE Research Online so that users may access research output of the 
School. Copyright © and Moral Rights for the papers on this site are retained by the individual 
authors and/or other copyright owners. Users may download and/or print one copy of any 
article(s) in LSE Research Online to facilitate their private study or for non-commercial research. 
You may not engage in further distribution of the material or use it for any profit-making activities 
or any commercial gain. You may freely distribute the URL (http://eprints.lse.ac.uk) of the LSE 
Research Online website.  
Practice of Epidemiology
Using a Nonparametric Multilevel Latent Markov Model to Evaluate Diagnostics
for Trachoma
Artemis Koukounari*, Irini Moustaki, Nicholas C. Grassly, Isobel M. Blake, María-Gloria Basáñez,
Manoj Gambhir, David C. W. Mabey, Robin L. Bailey, Matthew J. Burton, Anthony W. Solomon, and
Christl A. Donnelly
* Correspondence to Dr. Artemis Koukounari, Medical Research Council Centre for Outbreak Analysis and Modelling, Department of Infectious
Disease Epidemiology, Imperial College London, London, W2 1PG, United Kingdom (e-mail: artemis.koukounari@imperial.ac.uk).
Initially submitted February 8, 2012; accepted for publication August 8, 2012.
In disease control or elimination programs, diagnostics are essential for assessing the impact of interventions,
refining treatment strategies, and minimizing the waste of scarce resources. Although high-performance tests are
desirable, increased accuracy is frequently accompanied by a requirement for more elaborate infrastructure, which
is often not feasible in the developing world. These challenges are pertinent to mapping, impact monitoring, and
surveillance in trachoma elimination programs. To help inform rational design of diagnostics for trachoma elimina-
tion, we outline a nonparametric multilevel latent Markov modeling approach and apply it to 2 longitudinal cohort
studies of trachoma-endemic communities in Tanzania (2000–2002) and The Gambia (2001–2002) to provide
simultaneous inferences about the true population prevalence of Chlamydia trachomatis infection and disease
and the sensitivity, specificity, and predictive values of 3 diagnostic tests for C. trachomatis infection. Estimates
were obtained by using data collected before and after mass azithromycin administration. Such estimates are par-
ticularly important for trachoma because of the absence of a true “gold standard” diagnostic test for C. trachomatis.
Estimated transition probabilities provide useful insights into key epidemiologic questions about the persistence of
disease and the clearance of infection as well as the required frequency of surveillance in the postelimination
setting.
diagnosis; latent Markov model; multilevel; nonparametric model; trachoma
Abbreviations: LMM, latent Markov model; PCR, polymerase chain reaction; TF, trachomatous inflammation, follicular; TI, tra-
chomatous inflammation, intense.
An essential component of programs for the evaluation
and improvement of global health is the availability of accu-
rate diagnosis. Yet current diagnostics for many infectious
diseases do not meet the needs of the developing world (1).
Additionally, the lack of a diagnostic “gold standard” against
which the accuracy of these tests would be evaluated com-
pounds the problem. Trachoma, caused by ocular infection
with the bacterium Chlamydia trachomatis, is the leading
infectious cause of blindness in poor communities of devel-
oping countries (2) and is a disease with exactly these diag-
nostic challenges.
Although polymerase chain reaction (PCR)–based assays
are considered to be very sensitive and speciﬁc for the diag-
nosis of C. trachomatis infection, they are currently unavail-
able in trachoma-endemic settings and too expensive to be
used routinely as impact evaluation tools in large-scale treat-
ment programs. Therefore, the methods currently used to
evaluate the success of control strategies are clinical exami-
nations to detect the presence of active disease (trachomatous
inﬂammation, follicular (TF) and trachomatous inﬂamma-
tion, intense (TI)). The World Health Organization recom-
mends annual mass drug administration with azithromycin
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wherever the district prevalence of TF in children aged 1–9
years is 10% or greater (3). However, the diagnostic perfor-
mance of clinical examination is hindered by the frequent
presence of active disease in the absence of infection and of
infection in the absence of active disease (4–6). This is
partly because clinical signs of trachoma may persist for
many weeks after infection has been cleared (6–8) and also
may result when infections other than Chlamydia cause
trachoma-like inﬂammatory disease (9). Consequently, detec-
tion of active trachoma signs may not constitute the best
tool to evaluate control interventions. Furthermore, policy
makers require accurate surveillance of disease to decide
when treatment aimed at eliminating infection can be dis-
continued and to detect reemergence in previously treated
areas (10). Also of importance as implementation is roll-
ed out is the question of whether and how the diagnostic
performance of the available tests used at baseline may
change with initial endemicity and after mass drug adminis-
tration.
Latent variable modeling, that is statistical modeling that
includes unobserved random variables that can alternatively
be thought of as underlying parameters, has been used in
medical research for the analysis of diagnostic accuracy and
disease progression parameters in the absence of an accept-
able gold standard (11, 12), as in the case of trachoma. For
instance, Grassly et al. (13) used a multistate hidden Markov
model to estimate the median duration of active disease and
infection for different age groups by using a longitudinal
data set followed up every 2 weeks over a 6-month period in
The Gambia. Estimates were also obtained for the sensitivity
and speciﬁcity of PCR or for clinical symptoms for infec-
tion, but without distinguishing between TF and TI. Hidden
Markov models have been used to describe processes in
which an individual moves through a series of states in
continuous time, such as over the course of chronic and
infectious diseases (14–18), most often by using a single
diagnostic test. Through latent class analysis, 2 recent
studies evaluated the performance of the trachoma diagnos-
tics DNA-PCR, TF (i.e., detection of clinical symptoms of
TF), and TI (i.e., detection of clinical symptoms of TI) (10)
as well as DNA-PCR, RNA-PCR, and TF (19) by using
cross-sectional data from pretreatment and posttreatment
hyperendemic areas in Ethiopia, respectively. Latent class
analysis allows the results of several diagnostic tests to be
analyzed simultaneously, allowing for measurement error
and using the information from all the diagnostic indicators
to make a diagnosis for each individual in the study (20, 21).
In the current study, we developed latent Markov models
(LMMs), which we applied to 2 longitudinal data sets from
Tanzanian and Gambian communities with low baseline tra-
choma prevalence before and after mass administration of
azithromycin. We then assessed the diagnostic accuracy of
DNA-PCR, TF, and TI in the absence of a gold standard for
baseline and follow-up time points. LMMs can be seen as
an extension of latent class analysis for the analysis of longi-
tudinal data, and they have been proposed for public health
research in several studies (22–24). However, their applica-
tion to the evaluation of diagnostic accuracy has not, to our
knowledge, been previously investigated.
All models mentioned above—both hidden Markov
models and LMMs (i.e., extensions of continuous and dis-
crete Markov chains, respectively, that deal with measure-
ment error) as well as latent class analysis—are mixture
models. In the current study, we extended existing methodo-
logical research by ﬁtting multilevel LMMs and by allowing
some of the model parameters to differ across households.
This approach is novel in that it takes into consideration the
nested structure of the data and overcomes computational
challenges associated with multilevel longitudinal mixture
models; it allows for simultaneous evaluation of the 3 diag-
nostic tests with a test of measurement invariance as well as
evaluation of the effect of a mass drug administration–based
intervention on model-estimated infection and disease prev-
alence over time in the absence of a gold standard.
MATERIALS ANDMETHODS
Study areas, data collection, and analysis
Studies were conducted in East and West Africa (in the
Kahe Mpya subvillage of the Rombo District, Tanzania and
in the Upper Saloum District, The Gambia). The presence of
ocular C. trachomatis infections at baseline and follow-up
times was assessed through a DNA-PCR assay (Amplicor
PCR;RocheDiagnosticsCorp., Indianapolis, Indiana).Active
disease was deﬁned as the presence of TF and/or TI by using
the World Health Organization’s simpliﬁed grading system
(25). Detailed demographic information was collected,
including individual’s age, sex, and household membership.
Full descriptions of the study populations, structure of their
communities, laboratory methods used, and summary sta-
tistics have been published elsewhere (7, 26–31). We ﬁtted
models to the principal reservoir of infection (27) (i.e., chil-
dren aged <10 years) because trachoma control programs
currently make mass drug administration decisions on the
basis of the prevalence of active disease in children aged
1–9 years.
For all subjects, follow-up examinations and eye swab-
bing were performed by the same examiner at 2, 6, 12, 18,
and 24 months after mass drug administration in Tanzania
(during 2000–2002) and at 2, 6, 12, and 18 months in The
Gambia (during 2001–2002). In Tanzania, only 1 person
had a positive swab at 24 months (Figure 1); therefore, statis-
tical analysis was restricted to the ﬁrst 5 time points for this
data set. A single round of mass administration of azithro-
mycin was offered following baseline data collection to all
residents of communities participating in these studies.
Because the work presented here involves only further statis-
tical analyses of previously published, deidentiﬁed data
obtained in the original studies (28–31) (which had been
granted ethical approval), additional ethical approval was
not required.
Model specification for binary indicators
LMM consists of a structural model for the latent health
states (analogous to the latent classes in latent class analysis)
and a measurement model for the observed indicators (the 3
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diagnostic tools: PCR, TI, and TF) conditional on latent
health state.
Let Y{it} = (yi1t, . . ., yiPt) be a response pattern for the ith
individual at time t on P observed binary indicators (in this
study the observed indicators are the 3 binary diagnostic
tests, P = 3) with values 0 and 1 indicating negative and pos-
itive diagnostic test results, respectively.
We assume that for each subject, the true underlying
health state at each discrete time point t (where t = 1, . . ., T
and T = 5: baseline, 2, 6, 12, and 18 months) is explained by
a latent categorical variable denoted by C with J latent
health states.
The responses to the (P × T) y indicators are assumed to
be independent conditional on the latent health state mem-
bership, which in our analysis implies that the results from
the 3 diagnostics are assumed to be independent conditional
on the true underlying health state both within and across
time points. The latent categorical variable Ci,t depends on
Ci,t− 1 but not on earlier latent categorical variables, known
as the ﬁrst-order Markov property. Under these assumptions,
the probability of observing a particular response pattern Y
for a randomly selected individual i is the following:
PðYi ¼ yiÞ ¼
XJ
j1¼1
  
XJ
jTi¼1
PðCi;1 ¼ j1Þ
YTi
t¼2
PðCi;t ¼ jtjCi;t1 ¼ jt1Þ
YTi
t¼1
YP
p¼1
r ptjjtð1yiptÞð1 r ptjjtÞyipt ð1Þ
where
PðCi;1 ¼ j1Þ ¼
expðg j1Þ
1þPJ1k1¼1 expðgk1Þ
¼ h j1; ð2Þ
represents the baseline health state prevalence at the ﬁrst
time point (i.e., baseline), and
PðCi;t ¼ jtjCi;t1 ¼ jt1Þ ¼
expðg jt jjt1Þ
1þPJ1jt¼1 expðg jt jjt1Þ
¼ tCt jCt1 ; ð3Þ
represents the probability of a transition to latent health state
jt at time t conditional on membership in latent health state
jt− 1 at time t− 1. g jt jjt1 stands for the coefﬁcients from mul-
tinomial logistic regressions for transitions between t− 1
and t.
Furthermore, the probability of a negative response to pth
indicator at time t conditional on latent health state j at time
t is given by
Pðyipt ¼ 0jCi;t ¼ jÞ ¼ expðd pjtÞ1þ expðd pjtÞ ¼ r ptjjt: ð4Þ
The ρ quantities are known in the latent variable modeling
literature as the item response probabilities, and they show
precisely how the indicators (i.e., the diagnostic tests)
measure the latent health states. In the case where the latent
health states were dichotomous (identiﬁed as “not infected”
and “infected”) and 0 represented negative diagnostic test
results, equation 4 would represent the diagnostic speciﬁcity
for infection when Ci,t is a “not infected” health state and
Pðyipt ¼ 1jCi;t ¼ jÞ would represent the sensitivity for infec-
tion of the 3 diagnostics, respectively, when Ci,t is an
“infected” health state.
Depending on the number of latent health states (reﬂect-
ing combinations of infected/not infected with diseased/not
diseased), we derived estimates of sensitivities and speciﬁci-
ties as well as positive and negative predictive values for all
3 diagnostic tools for ocular chlamydial infection on the
basis of the estimates of η and ρ (equations 2 and 4) of
relevant latent health states. For more technical details,
see equations W6–W9 in the Web Appendix available at
Figure 1. Descriptive (proportion positive) results according to the
3 diagnostic tests under investigation (DNA-PCR for Chlamydia
trachomatis infection and TF and TI for signs of active trachoma
disease) for children aged <10 years prior to and after mass
azithromycin administration in A) Tanzania (2000–2002) and B) The
Gambia (2001–2002). Numbers of children participating at each time
point of the surveys are indicated in parentheses. PCR, polymerase
chain reaction; TF, trachomatous inflammation, follicular; TI,
trachomatous inflammation, intense.
Latent Markov Model to Evaluate Trachoma Diagnostics 915
Am J Epidemiol. 2013;177(9):913–922
 at London School of Econom
ics and Political Science on A
pril 11, 2014
http://aje.oxfordjournals.org/
D
ow
nloaded from
 
http://aje.oxfordjournals.org/. Figure 2 presents our LMM
model in a path diagram.
Table 1 summarizes the notation for our proposed
models.
Model selection
In mixture modeling, statistical theory determines the best
model that combines goodness of ﬁt and parsimony through
minimum values for information criteria. In the current
study, we explored these aspects among models that are
biologically plausible for the epidemiological settings studied
here (given the effect of mass drug administration on the
natural history of trachoma). The inspection of information
criteria informed our decisions (Web Table 1) and helped us
explore the initial speciﬁcations of simple LMMs that did
not account for household clustering of individuals. We
made decisions with respect to the number of latent health
states J required to obtain a good ﬁt.
1. We then tested whether the transition probability matrix
was stationary following treatment (i.e., 1 transition prob-
ability matrix between baseline and ﬁrst follow-up and
then another for subsequent transition periods vs. a sepa-
rate transition probability matrix for each transition
period). A global stationarity assumption (i.e., the equal-
ity of transition probability τ’s across each of the transi-
tion points in LMMs) was not tested because this was not
consistent with prior knowledge of mass drug administra-
tion impacts (28–30).
2. The hypothesis of measurement invariance of item
response probabilities ρ’s across time was also tested. In
general, if the ρ’s change over time, it is no longer as
clear how to interpret the transition probabilities τ’s
because along with interpreting quantitative changes in
latent health state membership, the meaning of the latent
health states change over time.
Clustering of infection by household is a key characteristic
of trachoma epidemiology (26). To allow for the nested
structure of our 2 data sets (individuals within households),
we expanded the selected model such that the categorical
latent variables had random intercepts that varied between
households. We used a discrete unspeciﬁed mixing distribu-
tion (i.e., nonparametric random-intercepts LMM) to examine
if there was between-household variation in the prevalence
of latent health states. We performed likelihood ratio tests
comparing simple and multilevel LMMs. Further details of
all models considered are given in the Web Appendix.
Maximum likelihood estimation and numerical
challenges
Maximum likelihood estimation of mixture modeling is
nontrivial and time consuming; it requires an iterative algo-
rithm because mixture models generally exhibit multiple
local maxima of the likelihood, and so ﬁtting procedures
Figure 2. Latent Markov modeling path diagram. The variables in boxes represent the 3 observed categorical indicators of the latent categorical
variables at each time point, Ct. The 4 arrows between the circled variables indicate the regression model for the latent categorical variable at time
point t on the latent categorical variable at time point t− 1. PCR, polymerase chain reaction; TF, trachomatous inflammation, follicular; TI,
trachomatous inflammation, intense.
Table 1. Latent Markov Model Notation
Symbol Definition
Structural model
C Categorical latent variable at the individual level
representing health (level 1)
η Proportion of individuals belonging in a specific
category of C/latent health state (or prevalence
of latent health state)
γ Coefficient for latent variable C
τ Transition probability
J Total number of latent health states
j Index for latent health states of C
Cba New categorical latent variable at the household
level (level 2) capturing the cluster variability in
the distribution of the level-1 latent health states
proportions
Measurement model
y Observed indicator (i.e., diagnostic test) of C
ρ Item response probability
i Index for individual
T Total number of observed time points varies
across individuals
t Index for time
p Index for diagnostic test
P Total number of observed indicators
n Sample size
δ Coefficient relating y to C
a See section, “Maximum likelihood estimation and numerical
challenges” andWeb Appendix for further technical details.
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must be based on many starting values to ensure that a
global maximum is found (32). In addition, maximum likeli-
hood estimation of mixture models with random effects
requires numerical integration, with each random effect with
a non-0 level-2 variance contributing 1 dimension of inte-
gration (33, 34). Such problems have been circumvented for
latent class analysis by the adoption of a nonparametric
approach in which the computation burden is much less
dependent on the number of random coefﬁcients (35–37).
We adopted this approach for LMM, with which we were
able to obtain a nonparametric random-intercepts LMM for
only the ﬁrst 4 of the 5 time points of the study (see
Figure 3). We ﬁtted all models by using MPlus, version 6.1,
software (38), which automatically uses appropriate iterative
algorithms and several sets of random starting values to
reduce the probability of obtaining a local solution. The
method of estimation was full information maximum likeli-
hood, in which we assumed that missing data were missing
at random. This means we assumed that missingness in
these data was related to the conditions of the data collection
rather than the latent health states of individuals. In Tanza-
nia, there were very high follow-up levels for the ﬁrst 5
years, whereas in The Gambia the main reason for people
not being seen at a particular follow-up appointment was
travel outside the study area. We also performed χ2 tests for
the missingness assumption. Such an approach allowed
maximum use of data from individuals with incomplete
(missing) data at the time points under study. Further techni-
cal details are given in the Web Appendix.
RESULTS
We ﬁtted measurement-invariant LMMs (because the
meaning of the latent health states also remains constant
over time for these models) with 2 and 4 transition probabil-
ity matrices for 2, 3, or 4 latent health states (Web Table 1).
For Tanzania, our results indicated that a model with 2 tran-
sition probability matrices (1 for the 0- to 2-month follow-
up and 1 for each subsequent follow-up period) and 3 latent
health states was the most appropriate. We considered a
similar model with 4 latent health states, but the item
response probabilities did not point to meaningful interpreta-
tion of the latent health states; thus, we chose the model with
3 latent health states. For The Gambia, our results indicated
that the model with 4 latent health states and 2 transition
probability matrices was the most appropriate. The pattern
of item response probabilities across the diagnostic tests
(shown in Table 2) clearly differentiates among the latent
health states and appears to correspond to different infection
and disease states. For these selected models, there was no
evidence that the missing at random assumption was vio-
lated (P values for χ2 test for missing completely at random
were 1.000). Nonparametric random effects on the latent
health states were signiﬁcant in both models (Web Table 2).
The models failed to converge when data from the ﬁnal
observation were included in each country, which was most
likely a result of the low prevalence of infection at this ﬁnal
follow-up time. We therefore present results based on the
ﬁrst 4 time points only. By examining the item response
Figure 3. Nonparametric multilevel latent Markov modeling path diagram with J latent health states (J = 4). The within-household model (level 1)
is similar to the model in Figure 2 with 3 observed categorical indicators and 4 measurement time points; the 3 single filled circles at the bottom of
each of the 4 Ct latent categorical variables represent the random means for the within-household latent health states (there are J− 1 random
means). These random means are referred to as C1 # 1 . . .. C4 # 3 in the between-household model (level 2), and they vary across level 2
between households (cluster level) latent classes (labeled Cb in the above diagram). PCR, polymerase chain reaction; TF, trachomatous
inflammation, follicular; TI, trachomatous inflammation, intense.
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probabilities ρ in Table 2, we assigned epidemiologically
relevant interpretations to the latent health states. The ﬁrst
latent health state, labeled as “not infected and not dis-
eased,” was characterized by very high probabilities of
yielding negative results in both countries in all 3 examined
diagnostic tests. Then, for Tanzania, “not infected and dis-
eased” and “infected and diseased” can be assigned to the
complementary corresponding probabilities of the second
and third latent health states, respectively. In The Gambia,
where a 4-state LMM was supported, the additional state
appeared to correspond to “infected and not diseased.”
Having assigned interpretations to the latent health states,
we examined the estimated prevalences η of these latent
health states over time (Figure 4). In both countries, the
majority of children fell into the latent health state deﬁned as
“not infected and not diseased.” However, the proportion of
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Figure 4. Estimates of prevalences η of latent health states over
time as calculated from the nonparametric multilevel latent Markov
model for A) Tanzania (2000–2002) and B) The Gambia (2001–
2002). I− /D− , not infected and not diseased; I + /D− , infected and
not diseased; I− /D + , not infected and diseased; I + /D + , infected
and diseased.
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those children who fell into this latent health state decreased
in Tanzania after 6 months post–mass drug administration,
whereas in The Gambia this proportion continued to increase
over the study period. On the other hand, the proportion of
children who fell into the latent health state, “not infected and
diseased,” also increased in Tanzania after 6 months post–
mass drug administration, whereas in The Gambia this propor-
tion continued to decrease over the study period.
Furthermore, we examined the transitions between the
latent health states over time by inspecting the elements of
the transition probability matrices (Tables 3 and 4). Diago-
nal elements represent being in a latent health state at time t,
conditional on being in that same latent health state at the
previous time (t − 1). As expected, most of these elements
were high in the nontreatment intervals. There was a higher
probability of clearance of disease in uninfected individuals
in The Gambia during both treatment and nontreatment
intervals (τ = 0.557 and 0.790, respectively) compared with
Tanzania (τ = 0.316 and 0.000, respectively).
Finally, by combining estimates of η and ρ and averaging
them over the 4 time points of study here (equations W6–
W9 in the Web Appendix), we were able to evaluate the
accuracy of all 3 diagnostic tests over time for ocular chla-
mydial infection for Tanzania and The Gambia (Table 5).
DISCUSSION
We applied nonparametric multilevel LMMs to 2 longitu-
dinal data sets from Tanzanian and Gambian communities
with low baseline trachoma prevalence before and after a
round of mass azithromycin administration. This latent vari-
able modeling approach yielded an average assessment of the
diagnostic accuracy of PCR, TF, and TI for the detection of
C. trachomatis infection in the absence of a gold standard.
We believe that our ﬁndings have important implications
for monitoring and evaluation of trachoma control programs.
For instance, TF is the measure on which mass drug admin-
istration decisions are often based.
The sensitivity and positive predictive value of clinical
examination for infection were estimated to be very low in
The Gambia, whereas the sensitivity of TI and positive pre-
dictive value of clinical examination (TF and TI) were very
low in Tanzania, which is problematic; if treatment decisions
are based solely on the simpliﬁed grading system, it could
potentially lead to the decision to continue the annual mass
administration of antichlamydial antibiotics for years after
C. trachomatis has been eliminated from recipient communi-
ties (39). TF had higher sensitivity but lower positive predic-
tive value and speciﬁcity for infection than did TI. The
sensitivity for infection of DNA-PCR was estimated to be
77.8% (95% conﬁdence interval, 41.5%, 94.5%) in Tanza-
nia and 79.0% (95% conﬁdence interval, 58.6%, 99.4%) in
The Gambia, which is comparable with estimates in Ethiopia
(19, 40). A model with variable sensitivity and speciﬁcity of
the diagnostic tests (varying item response probabilities)
over time was not supported by the data in The Gambia
(Web Table 1), although this may be the result of low power
given the low infection prevalence after treatment in this
community. In Tanzania, there was support for variable per-
formance of the diagnostic tests over time (Web Table 1).
Table 4. Transition Probability Results τ From the Nonparametric Multilevel Latent Markov Model for The Gambia, 2001–2002
Time t – 1a
Treatment Interval
(0–2 months), Time t
Nontreatment Intervals (2–6 months
and 6–12 months), Time t
I− /D− I + /D− I− /D+ I + /D + I− /D− I + /D− I− /D + I + /D +
I− /D− 0.980 0.000 0.016 0.004 0.985 0.000 0.015 0.000
I + /D− 0.721 0.000 0.279 0.000 0.000 1.000 0.000 0.000
I− /D + 0.557 0.000 0.443 0.000 0.790 0.040 0.170 0.000
I + /D + 0.000 0.000 1.000 0.000 0.434 0.000 0.566 0.000
Abbreviations: I− /D− , not infected and not diseased; I + /D− , infected and not diseased; I− /D + , not infected and diseased; I + /D + , infected
and diseased.
a Time t – 1 represents the index for the immediately previous time point in the study.
Table 3. Transition Probability Results τ From the Nonparametric Multilevel Latent Markov Model for Tanzania,
2000–2002
Time, t – 1a
Treatment Interval
(0–2 months), Time t
Nontreatment Intervals (2–6 months
and 6–12 months), Time t
I− /D− I− /D + I + /D + I− /D− I− /D + I + /D +
I− /D− 1.000 0.000 0.000 0.768 0.131 0.101
I− /D + 0.316 0.684 0.000 0.000 1.000 0.000
I + /D + 0.260 0.541 0.198 0.000 0.001 0.999
Abbreviations: I− /D− , not infected and not diseased; I + /D− , infected and not diseased; I− /D + , not infected
and diseased; I + /D + , infected and diseased.
a Time t – 1 represents the index for the immediately previous time point in the study.
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This complicates the interpretation of the latent health states;
therefore, in this analysis we focused on the model with
ﬁxed item response probabilities over time. However, further
work should explore the signiﬁcance of this variation over
time; because a temporal relationship between infection and
clinical disease will be driving the diagnostic performance
results, it is unlikely that TF would have the same predictive
value for infection at 2 or even 6 months after mass drug
administration as it would in treatment-naïve populations.
Our nonparametric multilevel modeling approach allowed
the latent health state prevalences to vary between house-
holds with the advantage of less strong distributional
assumptions and computational burden for the random
effects at the household level (Web Appendix). Maximum
likelihood estimation of a parametric multilevel LMM
(where a common factor would model the random means
and their associated covariances) would require 4 dimen-
sions of integration, resulting in large computational com-
plexity (32, 35, 36).
These ﬂexible nonparametric multilevel LMMs facilitated
evaluation of the effect of a mass drug administration–based
intervention on the prevalence of infection and disease over
time. This is particularly important because the use of mass
drug administration for trachoma control would ideally be
based on the true prevalence of C. trachomatis infection
(41). Such estimates may also shed light on the relationship
between the prevalence of clinical activity and chlamydial
infections for other comparable endemic settings. One of the
novelties of our methodology is that such quantities were
estimated by using latent variables, adjusting for the mea-
surement error contained in the diagnostic tests studied.
LMMs require only that there is a certain degree of correla-
tion among the different diagnostic tests; TF and TI convey
different information than does the PCR, and this is reﬂected
here in the formation of the latent health states. We recog-
nize though that our results depend upon the assumption of
conditional independence.
On the basis of the latent health state prevalences at each
time point alone, it is impossible to quantify how children
move between these latent health states over time. The tran-
sition probability matrices (Tables 3 and 4) provide par-
simonious yet detailed insights into key epidemiologic
differences regarding the persistence of disease and the
clearance of infection in the 2 studies. For instance, 1 of the
key ﬁndings was the persistence of disease in Tanzania
between 2 and 12 months, suggesting that tetracycline given
to TF cases after baseline had little effect. Furthermore, the
occurrence of disease resembling “active trachoma” in non-
infected individuals living in communities that are or have
recently been trachoma endemic is well documented (13,
42) and is the subject of ongoing research. The null or very
low transition probabilities from “not infected and not dis-
eased” to “infected and not diseased” might suggest a lack
of ﬁeld and laboratory cross-contamination of samples.
Also, within the nontreatment interval, perhaps the transition
from “infected and not diseased” to “not infected and not
diseased” would be high if there were contamination in the
samples between the different time points. However, we
believe that contamination would be most probable at single
time points among samples rather than between time points;Ta
b
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thus, such interpretations should be made cautiously here. In
addition, because of the designs of the longitudinal studies
(speciﬁcally the sampling times of measurements per-
formed), we recognize that these transition probabilities
might well underestimate the true change between these
latent health states over time (43). Because the time points
are unevenly spaced, we could have ﬁtted transition hazards
rather than transition probabilities (in other words, hidden
Markov models), but then only 1 diagnostic test would be
evaluated because it is not computationally tractable to
ﬁt such models to multiple diagnostic tests simultaneously.
Our ﬁtted models have a separate transition probability
matrix for the ﬁrst time period (0–2 months, in which mass
drug administration took place) and for subsequent transition
periods. Thus, we have assumed the same transition proba-
bility in 4- and 6-month periods. We believe that this approx-
imation is not crucial for our ﬁnal inferences. However, in
cases of less evenly spaced time points when simultaneous
evaluation of multiple diagnostic tests with measurement
error is not of primary interest, hidden Markov models
might be more appropriate as a method of analysis. If there
were more frequent evenly spaced measurements after mass
drug administration, a more accurate picture of the posttreat-
ment natural history of trachoma might emerge. We propose
that those designing longitudinal trachoma studies to inform
control programs consider the measurement frequency
carefully where resourcing could allow for more frequent
follow-up.
In conclusion, this study has demonstrated that nonpara-
metric multilevel LMMs can be used for the evaluation of
diagnostic tools for trachoma in the absence of a diagnostic
gold standard, even while allowing for the inherent hierarchi-
cal structure of these data: namely, repeated observations of
children within households. We recommend that these meth-
ods be applied in settings with moderate and high baseline
trachoma prevalence where longitudinal data can be gener-
ated before and after mass drug administration. Such research
will aid trachoma program managers in their efforts to iden-
tify and characterize useful measures to evaluate control
interventions. More generally, we recommend that LMMs be
used for the evaluation of diagnostic tests of other diseases
without gold standard diagnostic tools whenever longitudinal
data are available, because such methodology has greater
statistical power than does latent class analysis. Because
LMMs use the additional information provided by repeated
measurements, they might enable detection of additional
latent health states or latent classes than if a latent class anal-
ysis was used at each time point. Furthermore, LMMs permit
questions about changes in true health states and test the
measurement invariance hypothesis of the diagnostic tests of
interest over time, making them very useful tools for control
program monitoring and evaluation research.
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